XML 55 R43.htm IDEA: XBRL DOCUMENT
v3.20.2

BUSINESS DEVELOPMENT - Asset Acquisition, Narrative (Details) |  |  |  | 3 Months Ended | 9 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | ---
Dec. 31, 2020 USD ($) | Sep. 09, 2019 USD ($) asset | Jan. 04, 2019 USD ($) asset | Sep. 30, 2020 USD ($) | Sep. 30, 2019 USD ($) | Mar. 31, 2019 USD ($) | Sep. 30, 2020 USD ($) | Sep. 30, 2019 USD ($) | Dec. 31, 2019 USD ($)
Schedule Of Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |
In-process research and development |  |  |  | $ 0 | $ 59,889,000 |  | $ 0 | $ 59,889,000 |
Consortium of Focused Orthopedists, LLC | Disposal Group, Disposed of by Sale, Not Discontinued Operations | Subsequent Event | Forecast | Smith & Nephew USD Limited |  |  |  |  |  |  |  |  |
Schedule Of Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Sale of Extremity Orthopedics business, product development payment | $ 41,500,000 |  |  |  |  |  |  |  |
Rebound |  |  |  |  |  |  |  |  |
Schedule Of Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Upfront payment |  | $ 67,100,000 |  |  |  |  |  |  |
Contingent development milestone payments commitment (up to) |  | $ 35,000,000.0 |  |  |  |  |  |  |
Number of assets acquired | asset |  | 1 |  |  |  |  |  |  |
Remaining net assets acquired |  | $ 7,200,000 |  |  |  |  |  |  |
Development milestone |  |  |  |  |  |  |  |  | $ 5,000,000.0
In-process research and development |  |  |  |  |  |  |  |  | $ 5,000,000.0
Rebound | Cash and Cash Equivalents |  |  |  |  |  |  |  |  |
Schedule Of Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Remaining net assets acquired |  | 2,100,000 |  |  |  |  |  |  |
Rebound | Deferred Tax Asset |  |  |  |  |  |  |  |  |
Schedule Of Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Remaining net assets acquired |  | 4,200,000 |  |  |  |  |  |  |
Rebound | In-Process Research and Development Expense |  |  |  |  |  |  |  |  |
Schedule Of Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Upfront payment |  | $ 59,900,000 |  |  |  |  |  |  |
ISC |  |  |  |  |  |  |  |  |
Schedule Of Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Number of assets acquired | asset |  |  | 1 |  |  |  |  |  |
Research and development |  |  |  |  |  | $ 1,700,000 |  |  |
ISC | Enabling technology license |  |  |  |  |  |  |  |  |
Schedule Of Asset Acquisition [Line Items] |  |  |  |  |  |  |  |  |
Upfront payment, intangible assets |  |  | $ 1,700,000 |  |  |  |  |  |
Option to acquire, period subsequent to first commercial sale |  |  | 4 years |  |  |  |  |  |
Maximum future purchase price, if circumstances met (not to exceed) |  |  | $ 80,000,000.0 |  |  |  |  |  |

X
- Definition Asset Acquisition, Assets Acquired And Liabilities Assumed, Net + References No definition available. + Details
Name: | iart_AssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet
Namespace Prefix: | iart_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Asset Acquisition, Consideration Transferred + References No definition available. + Details
Name: | iart_AssetAcquisitionConsiderationTransferred
Namespace Prefix: | iart_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Asset Acquisition, Development Milestone Payment + References No definition available. + Details
Name: | iart_AssetAcquisitionDevelopmentMilestonePaymentToBePaid
Namespace Prefix: | iart_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Asset Acquisition, Maximum Contingent Development Milestone Payments + References No definition available. + Details
Name: | iart_AssetAcquisitionMaximumContingentDevelopmentMilestonePaymentsIfCircumstancesMet
Namespace Prefix: | iart_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Asset Acquisition, Maximum Future Consideration Transferred, If Circumstances Met + References No definition available. + Details
Name: | iart_AssetAcquisitionMaximumFutureConsiderationTransferredIfCircumstancesMet
Namespace Prefix: | iart_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Asset Acquisition, Number Of Assets Acquired + References No definition available. + Details
Name: | iart_AssetAcquisitionNumberOfAssetsAcquired
Namespace Prefix: | iart_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Asset Acquisition, Option To Acquire, Period Subsequent To Commercial Sale, If Circumstances Met + References No definition available. + Details
Name: | iart_AssetAcquisitionOptionToAcquirePeriodSubsequentToCommercialSaleIfCircumstancesMet
Namespace Prefix: | iart_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disposal Group, Including Discontinued Operation, Payment Related To Product Development + References No definition available. + Details
Name: | iart_DisposalGroupIncludingDiscontinuedOperationPaymentRelatedToProductDevelopment
Namespace Prefix: | iart_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition [Line Items] for Schedule Of Asset Acquisition [Table] + References No definition available. + Details
Name: | iart_ScheduleOfAssetAcquisitionLineItems
Namespace Prefix: | iart_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. + References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentInProcess
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=iart_ConsortiumofFocusedOrthopedistsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=iart_SmithNephewUSDLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | iart_AssetAcquisitionAxis=iart_ReboundTherapeuticsCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=iart_DeferredTaxAssetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | iart_AssetAcquisitionAxis=iart_IntegratedShoulderCollaborationInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |